|
|
|
Insider
Information: |
Edelman Joseph |
Relationship: |
Former 10% Owner |
City: |
New York |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
42 |
|
Direct
Shares |
630,171 |
|
Indirect Shares
|
332,164,708 |
|
|
Direct
Value |
$1,466,262 |
|
|
Indirect Value
|
$2,852,575,947 |
|
|
Total
Shares |
332,794,879 |
|
|
Total
Value |
$2,854,042,209 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
79
|
21
|
Stock
price went up :
|
50
|
11
|
Stock
price went down : |
29
|
10
|
|
|
|
Gain/Loss Ratio : |
1.7
|
1.1
|
Percentage
Gain/Loss : |
13.4%
|
197.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Penwest Pharmaceuticals Co |
PPCO |
10% Owner |
2008-06-23 |
0 |
2008-06-23 |
6,387,546 |
Premium* |
|
Synageva BioPharma Corp |
GEVA |
10% Owner |
|
0 |
2011-11-02 |
0 |
Premium* |
|
Aegerion Pharmaceuticals, Inc. |
AEGR |
10% Owner |
2012-11-01 |
133,133 |
2012-11-29 |
2,595,293 |
Premium* |
|
Acelrx Pharmaceuticals Inc |
ACRX |
10% Owner |
|
0 |
2017-06-19 |
4,533,728 |
Premium* |
|
Amicus Therapeutics Inc |
FOLD |
10% Owner |
|
0 |
2018-10-03 |
20,724,424 |
Premium* |
|
VBI Vaccines Inc |
VBIV |
10% Owner |
|
0 |
2014-07-25 |
2,610,356 |
Premium* |
|
Aldeyra Therapeutics, Inc. |
ALDX |
10% Owner |
|
0 |
2024-04-05 |
9,275,851 |
Premium* |
|
Aravive Inc |
ARAV |
10% Owner |
|
0 |
2017-09-22 |
2,099,563 |
Premium* |
|
Kadmon Holdings, Llc |
KDMN |
10% Owner |
|
0 |
2019-11-18 |
14,636,334 |
Premium* |
|
Zogenix, Inc. |
ZGNX |
10% Owner |
2017-09-29 |
0 |
2018-08-10 |
4,070,357 |
Premium* |
|
Global Blood Therapeutics, Inc. |
GBT |
10% Owner |
2017-12-19 |
0 |
2017-12-19 |
4,889,066 |
Premium* |
|
Corium International, Inc. |
CORI |
10% Owner |
2018-01-16 |
0 |
2018-10-12 |
2,724,686 |
Premium* |
|
Albireo Pharma Inc |
ALBO |
10% Owner |
2018-01-25 |
0 |
2022-10-13 |
1,939,723 |
Premium* |
|
Solid Biosciences Inc |
SLDB |
Director, 10% Owner |
2018-01-30 |
0 |
2024-01-11 |
6,906,646 |
Premium* |
|
La Jolla Pharmaceutical Co |
LJPC |
10% Owner |
2018-02-13 |
0 |
2019-01-08 |
2,253,376 |
Premium* |
|
Motus Gi Holdings Inc |
MOTS |
10% Owner |
2018-02-16 |
0 |
2021-01-22 |
2,660,542 |
Premium* |
|
Quotient Ltd |
QTNTQ |
10% Owner |
2018-05-22 |
0 |
2022-10-31 |
7,945,211 |
Premium* |
|
Dova Pharmaceuticals, Inc. |
DOVA |
10% Owner |
2018-06-04 |
0 |
2019-11-12 |
0 |
Premium* |
|
Meiragtx Holdings Plc |
MGTX |
10% Owner |
2018-06-08 |
0 |
2023-05-05 |
11,281,103 |
Premium* |
|
Crinetics Pharmaceuticals, Inc. |
CRNX |
10% Owner |
2018-07-20 |
0 |
2022-04-18 |
5,321,032 |
Premium* |
|
Agile Therapeutics Inc |
AGRX |
10% Owner |
2018-07-26 |
0 |
2021-10-13 |
21,654,485 |
Premium* |
|
Verrica Pharmaceuticals Inc. |
VRCA |
10% Owner |
2018-06-19 |
0 |
2023-12-29 |
7,099,182 |
Premium* |
|
Athenex, Inc. |
ATNX |
10% Owner |
2019-05-06 |
0 |
2020-09-14 |
13,532,467 |
Premium* |
|
ADMA Biologics Inc |
ADMA |
10% Owner |
2019-05-21 |
0 |
2021-09-30 |
13,262,375 |
Premium* |
|
Foamix Pharmaceuticals Ltd |
FOMX |
10% Owner |
|
0 |
2019-07-29 |
11,203,881 |
Premium* |
|
Lyra Therapeutics, Inc. |
LYRA |
Director, 10% Owner |
2020-05-05 |
0 |
2023-05-31 |
12,757,563 |
Premium* |
|
VYNE Therapeutics Inc |
VYNE |
10% Owner |
2020-06-09 |
0 |
2021-08-16 |
4,935,057 |
Premium* |
|
Leap Therapeutics, Inc. |
LPTX |
10% Owner |
2020-06-22 |
0 |
2020-06-22 |
8,476,496 |
Premium* |
|
Athira Pharma, Inc. |
ATHA |
Director, 10% Owner |
|
0 |
2023-12-29 |
5,402,964 |
Premium* |
|
Cerevel Therapeutics Holdings, I... |
CERE |
Director |
2020-10-20 |
0 |
2024-02-20 |
10,794,876 |
Premium* |
|
Scynexis Inc |
SCYX |
10% Owner |
2021-01-20 |
0 |
2021-01-22 |
1,800,000 |
Premium* |
|
Landos Biopharma, Inc. |
LABP |
Director, 10% Owner |
|
0 |
2021-02-09 |
17,960,839 |
Premium* |
|
Astria Therapeutics, Inc |
ATXS |
Director |
|
0 |
2024-02-01 |
6,485,420 |
Premium* |
|
Prometheus Biosciences, Inc. |
RXDX |
10% Owner |
2021-03-16 |
0 |
2021-03-16 |
3,314,032 |
Premium* |
|
Rain Therapeutics Inc. |
RAIN |
10% Owner |
2021-04-27 |
0 |
2021-10-12 |
2,487,019 |
Premium* |
|
Nautilus Biotechnology, Inc |
NAUT |
10% Owner |
2021-05-24 |
497,038 |
2021-12-08 |
9,111,151 |
Premium* |
|
Isoplexis Corp |
ISO |
10% Owner |
2021-10-12 |
0 |
2021-10-12 |
3,554,587 |
Premium* |
|
Lianbio |
LIAN |
Director, 10% Owner |
|
0 |
2024-02-15 |
57,575,533 |
Premium* |
|
Acrivon Therapeutics, Inc. |
ACRV |
10% Owner |
|
0 |
2024-04-11 |
5,360,858 |
Premium* |
|
Chembio Diagnostics Inc |
CEMI |
Former 10% Owner |
2023-04-04 |
0 |
2023-04-27 |
0 |
Premium* |
|
Soleno Therapeutics Inc |
SLNO |
10% Owner |
|
0 |
2023-06-06 |
2,207,753 |
Premium* |
|
Cargo Therapeutics, Inc. |
CRGX |
Former 10% Owner |
2023-11-14 |
0 |
2023-11-14 |
333,333 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
304 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 6 of 13
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
DOVA |
Dova Pharmaceuticals, Inc... |
10% Owner |
|
2018-06-11 |
4 |
B |
$29.18 |
$578,424 |
I/I |
19,700 |
3,125,851 |
1.5 |
- |
|
ALDX |
Aldeyra Therapeutics, Inc... |
10% Owner |
|
2022-08-03 |
4 |
B |
$5.84 |
$584,000 |
I/I |
100,000 |
10,901,985 |
1.5 |
% |
|
MOTS |
Motus Gi Holdings Inc |
10% Owner |
|
2021-01-20 |
4 |
S |
$1.80 |
$586,166 |
I/I |
(325,648) |
3,884,894 |
0 |
% |
|
ALDX |
Aldeyra Therapeutics, Inc... |
10% Owner |
|
2022-08-04 |
4 |
B |
$6.17 |
$586,767 |
I/I |
95,100 |
10,997,085 |
1.5 |
% |
|
CORI |
Corium International, Inc... |
10% Owner |
|
2018-01-16 |
4 |
B |
$11.83 |
$595,641 |
I/I |
50,350 |
5,897,483 |
1.5 |
- |
|
ALDX |
Aldeyra Therapeutics, Inc... |
10% Owner |
|
2022-07-28 |
4 |
B |
$5.00 |
$596,960 |
I/I |
119,392 |
10,023,271 |
1.5 |
% |
|
FOLD |
Amicus Therapeutics Inc |
10% Owner |
|
2018-09-21 |
4 |
B |
$12.53 |
$626,500 |
I/I |
50,000 |
20,674,424 |
1.5 |
- |
|
AEGR |
Aegerion Pharmaceuticals,... |
10% Owner |
|
2012-11-07 |
4 |
B |
$21.12 |
$633,600 |
I/I |
30,000 |
2,445,293 |
1.5 |
- |
|
ALDX |
Aldeyra Therapeutics, Inc... |
10% Owner |
|
2024-04-02 |
4 |
B |
$3.44 |
$640,015 |
I/I |
186,051 |
8,788,011 |
1.5 |
% |
|
ALDX |
Aldeyra Therapeutics, Inc... |
10% Owner |
|
2024-04-04 |
4 |
B |
$4.67 |
$655,112 |
I/I |
140,281 |
9,238,139 |
1.5 |
% |
|
QTNTQ |
Quotient Ltd |
10% Owner |
|
2022-10-31 |
4 |
S |
$0.08 |
$660,449 |
I/I |
(8,255,607) |
7,945,211 |
0 |
- |
|
AEGR |
Aegerion Pharmaceuticals,... |
10% Owner |
|
2012-11-29 |
4 |
B |
$22.71 |
$681,300 |
I/I |
30,000 |
2,595,293 |
1.5 |
- |
|
ATNX |
Athenex, Inc. |
10% Owner |
|
2019-10-16 |
4 |
B |
$10.29 |
$691,714 |
I/I |
67,222 |
10,802,467 |
1.5 |
- |
|
SCYX |
Scynexis Inc |
10% Owner |
|
2021-01-21 |
4 |
S |
$7.38 |
$701,100 |
I/I |
(95,000) |
2,120,000 |
0 |
% |
|
ALDX |
Aldeyra Therapeutics, Inc... |
10% Owner |
|
2022-08-08 |
4 |
B |
$7.24 |
$702,280 |
I/I |
97,000 |
11,235,085 |
1.5 |
% |
|
ADMA |
ADMA Biologics Inc |
10% Owner |
|
2021-08-18 |
4 |
S |
$1.29 |
$712,570 |
I/I |
(552,380) |
15,153,330 |
0 |
% |
|
DOVA |
Dova Pharmaceuticals, Inc... |
10% Owner |
|
2019-07-11 |
4 |
B |
$16.67 |
$715,410 |
I/I |
42,916 |
3,708,705 |
1.5 |
- |
|
DOVA |
Dova Pharmaceuticals, Inc... |
10% Owner |
|
2018-06-08 |
4 |
B |
$28.62 |
$716,200 |
I/I |
25,000 |
3,106,151 |
1.5 |
- |
|
ALDX |
Aldeyra Therapeutics, Inc... |
10% Owner |
|
2022-08-01 |
4 |
B |
$5.05 |
$728,134 |
I/I |
144,185 |
10,389,579 |
1.5 |
% |
|
AGRX |
Agile Therapeutics Inc |
10% Owner |
|
2019-11-14 |
4 |
B |
$1.69 |
$735,175 |
I/I |
435,015 |
6,586,125 |
1.5 |
- |
|
ALDX |
Aldeyra Therapeutics, Inc... |
10% Owner |
|
2022-08-09 |
4 |
B |
$7.50 |
$750,000 |
I/I |
100,000 |
11,335,085 |
1.5 |
% |
|
VYNE |
VYNE Therapeutics Inc |
10% Owner |
|
2021-08-12 |
4 |
S |
$2.23 |
$755,740 |
I/I |
(338,897) |
5,435,057 |
0 |
% |
|
MGTX |
Meiragtx Holdings Plc |
10% Owner |
|
2018-06-08 |
4 |
B |
$15.22 |
$761,000 |
I/I |
50,000 |
3,370,065 |
1.5 |
- |
|
ATNX |
Athenex, Inc. |
10% Owner |
|
2019-09-13 |
4 |
B |
$14.27 |
$805,056 |
I/I |
56,416 |
10,705,245 |
1.5 |
- |
|
ATHA |
Athira Pharma, Inc. |
Director |
|
2022-06-29 |
4 |
B |
$2.99 |
$807,300 |
I/I |
270,000 |
3,695,916 |
2.25 |
- |
|
304 Records found
|
|
Page 6 of 13 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|